Covid-19 roundup: AstraZeneca touts booster as effective against Omicron; Africa CDC reportedly in talks to buy Paxlovid
Though it still hasn’t received FDA authorization for its Covid-19 vaccine, AstraZeneca is charting a course for booster shots.
On Thursday, the British-Swedish pharma company revealed new information for its Vaxzevria shot, saying a booster dose significantly raised antibody levels against Omicron and other variants, including Delta, regardless of whether an individuals’ original vaccine series was AstraZeneca, an mRNA shot or Sinovac. AstraZeneca says it plans to submit the data to regulatory bodies worldwide.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.